Abstract:Objective: The mitochondrial nicotinamide adenine dinucleotide (NAD) kinase (MNADK) mediates de novo mitochondrial NADP biosynthesis by catalyzing the phosphorylation of NAD to yield NADP. In this study, we investigated the function and mechanistic basis by which MNADK regulates metabolic homeostasis.Methods: Generalized gene set analysis by aggregating human patient genomic databases, metabolic studies with genetically engineered animal models, mitochondrial bioenergetic analysis, as well as gain-and loss-of-function studies were performed to address the functions and mechanistic basis by which MNADK regulates energy metabolism and redox state associated with metabolic disease.Results: Human MNADK common gene variants or decreased expression of the gene are significantly associated with the occurrence of type-2 diabetes, non-alcoholic fatty liver disease (NAFLD), or hepatocellular carcinoma (HCC). Ablation of the MNADK gene in mice led to decreased fat oxidation, coincident with increased respiratory exchange ratio (RER) and decreased energy expenditure upon energy demand triggered by endurance exercise or fasting. On an atherogenic high-fat diet (HFD), MNADK-null mice exhibited hepatic insulin resistance and glucose intolerance, indicating a type-2 diabetes-like phenotype in the absence of MNADK. MNADK deficiency led to a decrease in mitochondrial NADP(H) but an increase in cellular reactive oxygen species (ROS) in mouse livers. Consistently, protein levels of the major metabolic regulators or enzymes were decreased, while their acetylation modifications were increased in the livers of MNADK-null mice. Feeding mice with a HFD caused S-nitrosylation (SNO) modification, a posttranslational modification that represses protein activities, on MNADK protein in the liver. Reconstitution of an SNO-resistant MNADK variant, MNADK-S193, into MNADK-null mice mitigated hepatic steatosis induced by HFD.Conclusion: MNADK, the only known mammalian mitochondrial NAD kinase, plays important roles in preserving energy homeostasis to mitigate the risk of metabolic disorders.(c) 2022 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

The key role of the NAD biosynthetic enzyme nicotinamide mononucleotide adenylyltransferase in regulating cell functions

NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells

Synthesis, Biological, and Computational Evaluations of Conformationally Restricted NAD-Mimics as Discriminant Inhibitors of Human NMN-Adenylyltransferase Isozymes

Exploring NAD + metabolism and NNAT: Insights from structure, function, and computational modeling

The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions

Regulation of and challenges in targeting NAD + metabolism

NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential

The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update

Technology and functional insights into the nicotinamide mononucleotide for human health

Complex Roles of Nicotinamide N-methyltransferase in Cancer Progression

NAD+ metabolism, stemness, the immune response, and cancer

The Vitamin Nicotinamide: Translating Nutrition into Clinical Care

Nicotinamide N-methyltransferase (NNMT): A key enzyme in cancer metabolism and therapeutic target

The Mitochondrial NAD Kinase Functions As a Major Metabolic Regulator Upon Increased Energy Demand

Nicotinamide Mononucleotide: Research Process in Cardiovascular Diseases

Nicotinamide Mononucleotide Supplementation: Understanding Metabolic Variability and Clinical Implications

Implications of altered NAD metabolism in metabolic disorders

Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death

NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health

Drug Discovery Targeting Nicotinamide Phosphoribosyltransferase (NAMPT): Updated Progress and Perspectives

NAMPT: A critical driver and therapeutic target for cancer